At EBMT 2025, Professor Alexandros Spyridonidis delivered a compelling presentation addressing one of the most pressing challenges in hematopoietic stem cell transplantation: how to provide patients with accurate, individualized prognostic information.
Based on data from over 24,000 patients in the ALWP database (2015–2021), the team developed a comprehensive multivariable model—the H-score—that integrates patient-, disease-, and transplant-specific factors such as age, performance status (KPS), comorbidities (HCT-CI), disease risk (DRI), and conditioning intensity (TCI). This holistic approach enables clinicians to move beyond a single average estimate (e.g., 56%) and offer personalized leukemia-free survival probabilities that can range from as low as 28% to as high as 65%, depending on the patient’s specific characteristics.
This score not only enhances therapeutic decision-making and informed consent but also offers a solid foundation for future clinical trials and comparative studies of emerging therapies. As Professor Spyridonidis concluded, the most informed decisions are still made by experienced and well-educated physicians—but now they can be made with better data.
